Biomed Central Ltd

SHERPA: Unknown

People

  1. Vickers
    Vickers
  2. Postow
    Postow
  3. D'Angelo
    D'Angelo
  4. Offit
    Offit
  5. Budhu
    Budhu
  6. Motzer
    Motzer
  7. Cheung
    Cheung
  8. Voss
    Voss
  9. O'Reilly
    O'Reilly
  10. Robson
    Robson

Groups

  1. Department of Medicine (556)
  2. Solid Tumor Oncology Division (454)
  3. GSK Faculty (290)
  4. Sloan Kettering Institute Postdocs (193)
  5. Population Sciences Research Program (158)
  6. Hematologic Malignancies, Division of (152)
  7. Epidemiology and Biostatistics (151)
  8. Melanoma and Immunotherapeutics Service (148)
  9. Survivorship Research (121)
  10. Surgery (118)
Search Within
Formats
  1. Journal Article (745)
  2. Meeting Abstract (257)
  3. Review (40)
  4. Guidelines (20)
  5. Editorial (10)
  6. Research Letter (7)
  7. Correspondence (4)
  8. Conference Paper (1)
  9. Miscellaneous (1)
Groups
  1. Department of Medicine (556)
  2. Solid Tumor Oncology Division (454)
  3. GSK Faculty (290)
  4. Sloan Kettering Institute Postdocs (193)
  5. Population Sciences Research Program (158)
  6. Hematologic Malignancies, Division of (152)

More Groups

People
  1. Jedd Wolchok (83)
  2. Taha Merghoub (55)
  3. Andrew Vickers (44)
  4. Michael Postow (43)
  5. Matthew Hellmann (30)
  6. Roberta Zappasodi (24)

More People

Years
  1. 2025 (28)
  2. 2024 (63)
  3. 2023 (45)
  4. 2022 (123)
  5. 2021 (91)
  6. 2020 (99)

More Years

Publications
  1. Journal for ImmunoTherapy of Cancer (404)
  2. Breast Cancer Research (67)
  3. BMC Cancer (64)
  4. Genome Biology (46)
  5. Journal of Hematology & Oncology (42)
  6. Journal of Translational Medicine (35)

More Publications

Results (1085)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Society for Immunotherapy of Cancer (SITC) recommendations on intratumoral immunotherapy clinical trials (IICT): From premalignant to metastatic disease
    Guidelines

    Luke, J. J.; Davar, D.; Andtbacka, R. H.; Bhardwaj, N.; Brody, J. D.; Chesney, J.; Coffin, R.; de Baere, T.; de Gruijl, T. D.; Fury, M.; more...
    Journal for ImmunoTherapy of Cancer (2024)

    Fulltext@MSK | Save
  • Targeting refractory/recurrent neuroblastoma and osteosarcoma with anti-CD3×anti-GD2 bispecific antibody armed T cells
    Journal Article

    Yankelevich, M.; Thakur, A.; Modak, S.; Chu, R.; Taub, J.; Martin, A.; Schalk, D.; Schienshang, A.; Whitaker, S.; Rea, K.; more...
    Journal for ImmunoTherapy of Cancer (2024)

    Fulltext@MSK | Save
  • Defining D-irAEs: Consensus-based disease definitions for the diagnosis of dermatologic adverse events from immune checkpoint inhibitor therapy
    Journal Article

    Chen, S. T.; Semenov, Y. R.; Alloo, A.; Bach, D. Q.; Betof Warner, A.; Bougrine, A.; Burton, L.; Cappelli, L. C.; Castells, M.; Cohen, J.; more...
    Journal for ImmunoTherapy of Cancer (2024)

    Fulltext@MSK | Save
  • Application of deep learning on mammographies to discriminate between low and high-risk DCIS for patient participation in active surveillance trials
    Journal Article

    Alaeikhanehshir, S.; Voets, M. M.; van Duijnhoven, F. H.; lips, E. H.; Groen, E. J.; van Oirsouw, M. C. J.; Hwang, S. E.; Lo, J. Y.; Wesseling, J.; Mann, R. M.; more...
    Cancer Imaging (2024)

    Fulltext@MSK | Save
  • Developing an educational “hub”: Impact of a distance-learning curriculum in a multinational cohort
    Journal Article

    Balbach, M. L.; Neely, G.; Yorke, A.; Figueroa-Medina, E.; Paly, J.; Shulman, R. M.; Dempsey, C.; Shulman, A.; Biancia, C. D.; Cutrer, W. B.; more...
    BMC Medical Education (2024)

    Fulltext@MSK | Save
  • Final results of urelumab, an anti-CD137 agonist monoclonal antibody, in combination with cetuximab or nivolumab in patients with advanced solid tumors
    Journal Article

    Khushalani, N. I.; Ott, P. A.; Ferris, R. L.; Cascone, T.; Schadendorf, D.; Le, D. T.; Sharma, M. R.; Barlesi, F.; Sharfman, W.; Luke, J. J.; more...
    Journal for ImmunoTherapy of Cancer (2024)

    Fulltext@MSK | Save
  • Suppressive effects of obesity on NK cells: Is it time to incorporate obesity as a clinical variable for NK cell-based cancer immunotherapy regimens?
    Editorial

    Canter, R. J.; Judge, S. J.; Collins, C. P.; Yoon, D. J.; Murphy, W. J.
    Journal for ImmunoTherapy of Cancer (2024)

    Fulltext@MSK | Save
  • Expert consensus guidelines on management and best practices for tumor-infiltrating lymphocyte cell therapy
    Guidelines

    Betof Warner, A.; Hamid, O.; Komanduri, K.; Amaria, R.; Butler, M. O.; Haanen, J.; Nikiforow, S.; Puzanov, I.; Sarnaik, A.; Bishop, M. R.; more...
    Journal for ImmunoTherapy of Cancer (2024)

    Fulltext@MSK | Save
  • A risk analysis of alpelisib-induced hyperglycemia in patients with advanced solid tumors and breast cancer
    Journal Article

    Rodón, J.; Demanse, D.; Rugo, H. S.; Burris, H. A.; Simó, R.; Farooki, A.; Wellons, M. F.; André, F.; Hu, H.; Vuina, D.; more...
    Breast Cancer Research (2024)

    Fulltext@MSK | Save
  • Advancing patient-centered research practices in a pragmatic patient-level randomized clinical trial: A thematic analysis of stakeholder engagement in Emergency Medicine Palliative Care Access (EMPallA)
    Journal Article

    Zhao, N.; Cuthel, A. M.; Storms, O.; Zhang, R.; Yamarik, R. L.; Hill, J.; Kaur, R.; Van Allen, K.; Flannery, M.; Chang, A.; more...
    Research Involvement and Engagement (2024)

    Fulltext@MSK | Save